$NTRA

BOTHA ROELOF sold $548K of NTRA (indirect holdings)

BOTHA ROELOF sold 2,450 indirectly-held shares of Natera, Inc. (NTRA) at $223.83 ($0.55M total) on 2026-06-01.

Original reporting
SEC EDGAR · BOTHA ROELOF
Published Jun 3, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates insider ownership records; it does not introduce new guidance, trial results, contracts, or litigation.

02

Market read

Traders may note the insider sale as a minor sentiment input, but it is unlikely to drive a sustained repricing without corroborating fundamental news.

03

What to watch

The filing does not specify motivation, and the absence of a stated 10b5-1 plan does not by itself confirm bearish information.

Relevance 6/10Novelty 6/10Timing: After-hours/filing dated June 3 for a June 1 sale

Background

This is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera director BOTHA ROELOF sold 2,450 shares in an open-market transaction disclosed via SEC Form 4 on June 1.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure without accompanying operational/financial news; also notes no 10b5-1 plan, but the sale size is still relatively small versus typical institutional flows.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect negative expectations, especially without a clear linkage to new events.

Key entities

  • Natera, Inc.

    Company whose director insider sale was disclosed (Form 4).

  • BOTHA ROELOF

    Director who sold 2,450 shares at ~$223.8265 on 2026-06-01.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.